Proposed Prognostic Model for CNS Risk in Aggressive B-Cell Lymphoma Validated
Investigators validated the German High-Grade Non-Hodgkin Lymphoma Study Group’s new prognostic model for aggressive B-cell lymphoma.
ASH 2014
R-CHOP Alone Induces High Complete Response in Non-Bulky Large B Cell Lymphoma
Addition of radiotherapy should be reserved for the minority of patients with non-bulky limited-stage diffuse large B cell lymphoma (DLBCL).
Pomalidomide, Bortezomib, Dexamethasone Highly Effective in Lenalidomide-Refractory Multiple Myeloma
Pomalidomide, bortezomib, and dexamethasone is a highly effective combination in multiple myeloma refractory to lenalidomide.
CTL019 Cells Demonstrate Strong Response in Pediatric Patients with Acute Lymphocytic Leukemia
CTL019 cells cause strong, durable responses in pediatric patients with relapsed, refractory acute lymphocytic leukemia (ALL).
Clinical Benefit Observed with Pembrolizumab in Heavily Pretreated Classical Hodgkin Lymphoma
Patients with classical Hodgkin lymphoma (cHL) who were heavily pretreated had clinical benefit from pembrolizumab (MK-3475).
Pacritinib Suppresses Leukemic Outgrowth in FLT3-ITD-Driven Acute Myeloid Leukemia (AML)
Pacritinib suppresses leukemic outgrowth from stroma-adherent cells in FLT3-ITD-driven acute myeloid leukemia (AML).
Once Weekly Carfilzomib Effective in Treatment-Naïve Multiple Myeloma
Multiple myeloma patients who received once-weekly carfilzomib with cyclophosphamide, dexamethasone had improved responses.
Early Thymic Precursor Found to Lack Significance in Children with T-Lymphoblastic Leukemia (T-ALL)
The largest study of T-lymphoblastic leukemia (T-ALL) ever conducted demonstrated “an excellent outcome” with standard four-drug induction.
Rituximab Improves Outcomes for Treatment-Naïve Young Patients with Mantle Cell Lymphoma
Rituximab should be used as maintenance therapy for the treatment of young previously untreated patients with mantle cell lymphoma.
Lenalidomide Induces Ubiquitination, Degradation of CSNK1A1 in Myelodysplastic Syndrome
Lenalidomide induces the ubiquitination and degredation of casein kinase 1A1 (CSNK1A1) by the CRBN-CRL4 E3 ubquitin ligase.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASH 2014
